Actelion acquires rights to Xiaflex/Xiapex from Auxilium Pharma

Actelion will acquire from Auxilium Pharma exclusive rights to commercialise Xiaflex (collagenase Clostridium histolyticum) as a treatment for two rare progressive collagen deposit conditions, Dupuytren�s contracture and Peyronie�s disease, in Canada, Australia, Brazil and Mexico.Xiaflex has already been approved in the US and the EU to treat Dupuytren�s contracture, a fibroproliferative disease in which abnormal collage deposits result in nodules and rope-like cords in the hand, and it is under regulatory review in Canada. Development work on the Dupuytren�s indication in Japan is underway.